Kinase inhibitor profiling using chemoproteomics

Methods in Molecular Biology

Volumn 795, Issue , 2012, Pages 161-177

  Schirle, Markus ^a   Petrella, Eugene C ^a   Brittain, Scott M ^a   Schwalb, David ^a   Harrington, Edmund ^a   Cornella Taracido, Ivan ^a   Tallarico, John A ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Chemoproteomics; Isobaric mass tags; Quantitative proteomics; Target identification

Indexed keywords

ENZYME INHIBITOR; PEPTIDE; PHOSPHOTRANSFERASE;

AFFINITY CHROMATOGRAPHY; ARTICLE; BINDING COMPETITION; CELL STRAIN K 562; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ASSAY; HELA CELL; HUMAN; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PROTEIN BINDING; PROTEOMICS; STAINING; TUMOR CELL LINE;

BINDING, COMPETITIVE; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; ENZYME ASSAYS; ENZYME INHIBITORS; HELA CELLS; HUMANS; K562 CELLS; MASS SPECTROMETRY; PEPTIDES; PHOSPHOTRANSFERASES; PROTEIN BINDING; PROTEOMICS; STAINING AND LABELING;

EID: 80555144285     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-337-0_11     Document Type: Article

References (16)

1. Fabian, M. A., Biggs, W. H., III, Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., Ford, J. M., Galvin, M., Gerlach, J. L., Grotzfeld, R. M., Herrgard, S., Insko, D. E., Insko, M. A., Lai, A. G., Lelias, J. M., Mehta, S. A., Milanov, Z. V., Velasco, A. M., Wodicka, L. M., Patel, H. K., Zarrinkar, P. P., and Lockhart, D. J. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat.Biotechnol. 23, 329-336. (Pubitemid 41094421)
2. Vesely, J., Havlicek, L., Strnad, M., Blow, J. J., Donella-Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., and Leclerc, S. (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur.J. Biochem. 224, 771-786. (Pubitemid 24282865)
3. Hall, S. E. (2006) Chemoproteomics-driven drug discovery: addressing high attrition rates. Drug Discovery Today 11, 495-502.
4. Rix, U. and Superti-Furga, G. (2009) Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5, 616-624.
5. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044. (Pubitemid 47517638)
6. Oppermann, F. S., Gnad, F., Olsen, J. V., Hornberger, R., Greff, Z., Keri, G., Mann, M., and Daub, H. (2009) Large-scale proteomics analysis of the human kinome. Mol.Cell Proteomics. 8, 1751-1764.
7. Graves, P. R., Kwiek, J. J., Fadden, P., Ray, R., Hardeman, K., Coley, A. M., Foley, M., and Haystead, T. A. (2002) Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol.Pharmacol. 62, 1364-1372. (Pubitemid 35403831)
8. Ong, S. E., Schenone, M., Margolin, A. A., Li, X. Y., Do, K., Doud, M. K., Mani, D. R., Kuai, L., Wang, X., Wood, J. L., Tolliday, N. J., Koehler, A. N., Marcaurelle, L. A., Golub, T. R., Gould, R. J., Schreiber, S. L., and Carr, S. A. (2009) Identifying the proteins to which smallmolecule probes and drugs bind in cells. Proc. Natl. Acad. Sci. USA 106,4617-4622.
9. Sharma, K., Weber, C., Bairlein, M., Greff, Z., Keri, G., Cox, J., Olsen, J. V., and Daub, H. (2009) Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741-744.
10. Garcia-Echeverria, C., Kanazawa, T., Kawahara, E., Masuya, K., Matsuura, N., Miyake, T., Ohmori, O., and Umemura, I. (2004) Preparation of novel 2,4-di(phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. PCT Int. Appl. WO2004080980 A1 20040923.
11. Baenteli, R., Zenke, G., Cooke, N. G., Duthaler, R., Thoma, G., Von Matt, A., Honda, T., Matsuura, N., Nonomura, K., Ohmori, O., Umemura, I., Hinterding, K., and Papageorgiou, C. (2003) Pyrimidine derivatives. PCT Int. Appl. WO 2003078404 A1 20030925.
12. Duthaler, R., Gerspacher, M., Holzer, P., Streiff, M., Thoma, G., Waelchli, R., and Zerwes, HG. (2007) Preparation of 2,4-di(arylamino)- pyrimidine-5-carboxamides as JAK kinases inhibitors. PCT Int. Appl. WO 2008009458 A1 20080124.
13. Garcia-Echeverria, C., Kanazawa, T., Kawahara, E., Masuya, K., Matsuura, N., Miyake, T., Ohmori, O., Umemura, I., Steensma, R., Chopiuk, G., Jiang, J., Wan, Y., Zhang, Q., Gray, N. S., and Karanewsky, D. (2004) Preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. PCT Int. Appl. WO2005016894 A1 20050224.
14. Argade, A., Singh, R., Li, H., Carroll, D., and Catalano, S. (2004) 2,4-pyrimidinediamine compounds and uses as antiproliferative agents. PCT Int. Appl. WO 2005013996 A2 20050217.
15. Bantscheff, M., Boesche, M., Eberhard, D., Matthieson, T., Sweetman, G., and Kuster, B. (2008) Robust and sensitive iTRAQ quantification on an LTQ Orbitrap mass spectrometer. Mol.Cell Proteomics. 7, 1702-1713.
16. Jaffe, J. D., Keshishian, H., Chang, B., Addona, T. A., Gillette, M. A., and Carr, S. A. (2008) Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification. Mol.Cell Proteomics. 7, 1952-1962.